Vimarsana
Biggest News Aggregation in the World

Page 2 - Not Reached News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Not Reached. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Not Reached Today - Breaking & Trending Today

Prof. Osman Müftüoğlu'ndan köşe komşusu Ertuğrul Özkök'e: Neyse ki sonunda 'pes etmese' de yanlış yolda olduğunu kabul etti - Vimarsana News

Prof. Osman Müftüoğlu'ndan köşe komşusu Ertuğrul Özkök'e: Neyse ki sonunda 'pes etmese' de yanlış yolda olduğunu kabul etti

Prof. Osman Müftüoğlu'ndan köşe komşusu Ertuğrul Özkök'e: Neyse ki sonunda ‘pes etmese’ de yanlış yolda olduğunu kabul etti

Source: t24.com.tr
Iovance Biotherapeutics Announces 33-Month Follow Up Data - Vimarsana News

Iovance Biotherapeutics Announces 33-Month Follow Up Data

Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel...

IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma - Vimarsana News

IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma

IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma - Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pre-treated (out to 7L / 8L) MUM patients, where historical 1-year OS Rate has been reported at 37% - Darovasertib monotherapy median Overall Survival in MUM is 13.2 months, where historical median OS has been reported at approximately 7 months - Darovasertib and binimetinib combination reports 2 partial responses (PR), ...